Cargando…

Progress in the application and mechanism of metformin in treating non-small cell lung cancer

At present, the incidence and mortality of lung cancer demonstrate an increasing trend. Non-small cell lung cancer (NSCLC) accounts for ~80–85% of all lung cancer cases. Therefore, developing novel and more effective treatments is of great importance. The use of combination therapies, where several...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chan, Xue, Yang, Xi, Yu-Rong, Xie, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431600/ https://www.ncbi.nlm.nih.gov/pubmed/28529553 http://dx.doi.org/10.3892/ol.2017.5862

Ejemplares similares

Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
por: Wang, Haocheng, et al.
Publicado: (2020)

Addition of metformin to non‐small‐cell lung cancer patients with or without diabetes
por: Chen, Hua‐Fen, et al.
Publicado: (2022)

Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum
por: Wen-Xiu, Xin, et al.
Publicado: (2018)

Research progress on the therapeutic effect and mechanism of metformin for lung cancer
por: Han, Pengkai, et al.
Publicado: (2022)

Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation
por: Wang, Yifan, et al.
Publicado: (2022)

Prognostic value of metformin for non-small cell lung cancer patients with diabetes
por: Xu, Tongbai, et al.
Publicado: (2018)

Advances in metformin-based metabolic therapy for non-small cell lung cancer
por: Chen, Na, et al.
Publicado: (2022)

The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Yang, Jieun, et al.
Publicado: (2022)

Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy
por: Xi, Yu, et al.
Publicado: (2022)

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
por: Wang, Yan, et al.
Publicado: (2023)

Metformin synergistic pemetrexed suppresses non‐small‐cell lung cancer cell proliferation and invasion in vitro
por: Zhang, Yan, et al.
Publicado: (2017)

Progress and application of circulating tumor cells in non-small cell lung cancer
por: Qian, Huizhu, et al.
Publicado: (2021)

Retracted: Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells
por: Ko, Eunjeong, et al.
Publicado: (2020)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Metformin in Pregnancy: Mechanisms and Clinical Applications
por: Hyer, Steve, et al.
Publicado: (2018)

Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI
por: Liu, Yu-Tao, et al.
Publicado: (2019)

RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non‐small cell lung cancer cells
por: Ma, Ke, et al.
Publicado: (2021)

Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2
por: Huang, Sha, et al.
Publicado: (2020)

Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
por: Tanino, Ryosuke, et al.
Publicado: (2018)

The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer
por: Wang, Yu, et al.
Publicado: (2015)

Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma
por: Gong, Kaikai, et al.
Publicado: (2020)

Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
por: Arrieta, Oscar, et al.
Publicado: (2016)

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
por: Cao, Nini, et al.
Publicado: (2020)

Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway
por: Yu, Chenxiao, et al.
Publicado: (2017)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Jingwen, et al.
Publicado: (2021)

Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020)

Correction to: The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer
por: Wang, Yu, et al.
Publicado: (2019)

Research Progress of Population Pharmacokinetic of Metformin
por: Wang, Xiaohu, et al.
Publicado: (2022)

Metformin Prevents or Delays the Development and Progression of Osteoarthritis: New Insight and Mechanism of Action
por: He, Miao, et al.
Publicado: (2022)

The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index
por: Zhang, Ting, et al.
Publicado: (2021)

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors
por: Afzal, Muhammad Z, et al.
Publicado: (2019)

Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

MicroRNA-520a Suppresses Pathogenesis and Progression of Non-Small-Cell Lung Cancer through Targeting the RRM2/Wnt Axis
por: Xie, Yi, et al.
Publicado: (2021)

RIOK1 is associated with non-small cell lung cancer clinical characters and contributes to cancer progression
por: Wang, Rong, et al.
Publicado: (2022)

Overexpression of JAM-A in Non-Small Cell Lung Cancer Correlates with Tumor Progression
por: Zhang, Min, et al.
Publicado: (2013)

The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease
por: Zeng, Ya, et al.
Publicado: (2020)

Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer
por: Ma, Ying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gutncahu1lv7ob3r9mbhrrkgod